The global anti-fungal treatment market is steadily growing due to rising infections and advanced therapies

From GlobeNewswire: 2024-12-10 08:12:00

The Anti-Fungal Treatment Market is valued at USD 16 Billion in 2023, set to reach USD 22.19 Billion by 2032 with a CAGR of 3.75%. Demand is driven by chronic conditions like cancer and HIV/AIDS, as well as antibiotic resistance. Advanced therapies and improved diagnostics support market growth.

Superficial Antifungal Infections dominate the market with 67% of revenue in 2023. Systemic Antifungal Infections are projected to grow at a CAGR of 5.33% from 2024 to 2032 due to an increasing number of immunocompromised individuals. Dermatology Clinics lead the market, but Hospitals & Clinics are expected to grow rapidly.

Oral Drugs hold the largest share of the Anti-Fungal Treatment Market at 55% in 2023. Ointments are anticipated to grow at a CAGR of 4.92% from 2024 to 2032 due to their ease of application and fewer systemic side effects. North America leads the market, but Asia Pacific is projected to grow the fastest at 6.02% CAGR from 2024 to 2032. The demand for antifungal treatments is rising in emerging markets like India and China, driven by expanding middle-class populations and improved healthcare systems. In 2023, Sandoz acquired global rights to Mycamine, enhancing its anti-infectives portfolio. GSK and SCYNEXIS also signed an exclusive agreement to commercialize Brexafemme for fungal infections. Market analysis includes factors like healthcare spending, market dynamics, and competitive landscape. SNS Insider offers in-depth market research and consulting services globally to help clients navigate changing market conditions with confidence.



Read more at GlobeNewswire: Anti-Fungal Treatment Market Sees Steady Growth Driven by